4CPS-024 Human normal immunoglobulin requirements in paediatric patients with primary immunodeficiency, focusing on the administration route switching

BACKGROUND: Human normal immunoglobulin (HNIg) indications are replacement. This therapy can be administered intravenously monthly (IVIG) or subcutaneously weekly (SCIG). Due to the possibility of self-administration and a better safety profile of SCIG, this route is being increasingly preferred by...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Eur J Hosp Pharm
Prif Awduron: Busquets, F Bossacoma, Martínez, A Deyà, Suárez, J Arrojo, Celma, M Sánchez, Escoda, A Comes, de Lara, LAlsina Manrique
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: BMJ Group 2018
Pynciau:
Section 4: Clinical pharmacy services
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7535718/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.115
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg